Review Article
Year: 2022 | Month: June | Volume: 12 | Issue: 6 | Pages: 89-92
DOI: https://doi.org/10.52403/ijhsr.20220611
A Review of Clinical Management of Drug Resistant Epilepsy
Aiperi Almanbekova
Neurology Resident, Osh State University, Osh, Kyrgyzstan
ABSTRACT
Epilepsy is one of the most prevalent chronic neurological illnesses, with an estimated frequency of 0.5% to 1%. Currently, the majority of epilepsy treatment methods include the provision of symptomatic medicine. When treating individuals with drug-resistant epilepsy (DRE), it is essential to provide anti-seizure medicines (ASDs) at an appropriate daily dose to prevent seizures with DRE. Because of drug resistance, about one-third of epileptic patients are still unable to take their drugs, despite the fact that the number of ASDs accessible continues to expand. Several risk factors, including epilepsy that started in infancy, symptoms of epilepsy, and abnormal neurological examination, increase the likelihood that a newly diagnosed epileptic patient would proceed to DRE. ASD poly-therapy is a kind of pharmacological treatment that is widely used. When assessing the influence of DRE on mental health and social integration, it is vital to make complete therapy modifications in order to improve the overall quality of life of patients.
Key words: Seizure, Epilepsy, Drug Resistant Epilepsy.